Great read on the PR BK...helps to have someone interpret what the words actually mean. I still think there are some significant catalysts coming up in the very short term. For example, I find it interesting that the safety board met on K but nothing has been said about the next cohort other than the conference in early January. Typically I thought we heard about the next cohort very soon after the safety board meets but perhaps I am wrong....this is what the November 24 PR said "The Company anticipates that the Kevetrin trial is nearing its conclusion with the start of the tenth cohort next month".
If anything, I think this is good news like Kelt said...if it was bad news they would have to release the information. I recognize it could simply be a delay, but it is a little odd. Here's hoping for a surprise!